Amulet Capital Announces Partnership with Peloton Advantage

Terms of the transaction were not disclosed.

Headquartered in Parsippany, NJ, Peloton was founded in 2005 and is a leading provider of clinical-focused strategic consulting and scientific communication services, including publication planning and medical writing. Peloton is very highly regarded by its clients and is viewed as a quality provider with strong therapeutic expertise, as well as outstanding project and account management capabilities. Peloton teams support US and global accounts for large and small clients, contributing to the success of more than 90 products spanning all major therapeutic areas.

Medical Affairs is considered to be the “third pillar” of pharmaceutical operations, serving as the bridge between R&D and Commercial activities. Medical Affairs has evolved into a separate function to establish, monitor, and support commercial products during drug launch preparation and post approval. Given the complexity and far-reaching responsibility of Medical Affairs today, these departments are now considered strategic to the long-term success of any drug.

The growth in Peloton’s business reflects an increased emphasis within the broader Medical Affairs industry on Health Economics and Outcomes Research (HEOR). The Company sees tremendous potential for future growth through the ongoing enhancement of its own HEOR expertise. The partnership with Amulet will help accelerate Peloton’s efforts toward building an industry-leading HEOR department, as well as enhance other offerings, such as innovative digital solutions.

Carolyn S. Clark, MBA, Co-Founder and President of Peloton said, “We are excited to work with the team at Amulet as Peloton embarks on this new chapter. We believe this is a very compelling relationship for Peloton, our employees, and our clients. The team at Amulet shares our vision of expanding our service offerings into adjacent business lines and expanding our geographic footprint to better serve our clients.”

Michael J. McLaughlin, MD, Co-Founder and Chief Scientific Officer of Peloton commented, “The team at Amulet has extensive experience and a very successful track record of investing in the outsourced pharmaceutical services industry. We are confident that this transaction will enable Peloton to pursue the next phase of our growth strategy.”

Ramsey Frank, Partner and Co-Founder of Amulet said, “In an environment of increasing transparency in scientific communications processes and clinical trial data, and the increasing scientific complexity of drugs, the global Medical Affairs market is expected to grow significantly in the next few years. Peloton’s strong historical financial performance, coupled with unmatched scientific knowledge, strategic insights, and an impressive network of thought-leaders, technology innovators, and long-standing industry experts position the company to take advantage of this growth opportunity. We are excited to make this investment in an excellent platform, and look forward to partnering with Carolyn Clark and Michael McLaughlin to continue to expand into new markets and reach out to new clients.”

BMO Sponsor Finance provided debt financing for the transaction. Petsky Prunier LLC acted as exclusive financial advisor to Peloton. Amulet was advised by Latham & Watkins LLP and Peloton by Gibbons PC.

About Peloton Advantage, LLC

Peloton Advantage, LLC is a privately owned medical communications company specializing in strategic publication planning and associated content development for medical education programs. Peloton’s teams support US and global accounts for large and small pharmaceutical, biotechnology, and medical device companies, contributing to the success of more than 90 products spanning all major therapeutic areas. For more information on Peloton Advantage, please visit www.pelotonadvantage.com.

About Amulet Capital Partners, LP

Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. Amulet Capital Partners’ investment team has approximately 50 years of private equity experience. For additional information, please visit www.amuletcapital.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005172/en/